BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• BioForest

  CombiMatrix Corporation Set to Join Russell Microcap Index

  June 25, 2008

   · 

  1 min read
• Drug Development

  VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) Announces Publication of Preclinical Data for the Company’s Avian Flu Vaccine Candidate in PLoS ONE Journal

  June 25, 2008

   · 

  1 min read
• Business

  LCA-Vision Announces CFO Change

  June 25, 2008

   · 

  1 min read
• Biotech Bay

  StemCells Inc. Files Replacement Shelf Registration Statement

  June 25, 2008

   · 

  1 min read
• Business

  BayBio (Bay Area Bioscience Association), BIOCOM and SoCalBio Establish the California Life Science Alliance

  June 25, 2008

   · 

  1 min read
• Drug Development

  Burnham Institute for Medical Research Release: Nerve Cells Derived from Embryonic Stem Cells and Transplanted into Mice May Lead to Improved Brain Treatments

  June 25, 2008

   · 

  1 min read
• Business

  Lixte Biotechnology Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs

  June 25, 2008

   · 

  3 min read
• Drug Development

  MethylGene Announces the Initiation of Trial 013

  June 25, 2008

   · 

  4 min read
• Pharm Country

  Axela Biosensors Inc. Expands Emergency Department Research Screening Study for Silent Brain Injury at Children’s Hospital of Pittsburgh of University of Pennsylvania Medical Center

  June 25, 2008

   · 

  1 min read
• Policy

  Ranbaxy Laboratories Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets; ‘First-to-File’ Status Will Provide 180-Day Marketing Exclusivity Upon Final Approval

  June 25, 2008

   · 

  2 min read